Live Breaking News & Updates on மாற்றத்தக்கது கடன் குறிப்புகள்
Stay updated with breaking news from மாற்றத்தக்கது கடன் குறிப்புகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so; ....
5 May 2021 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received a conversion notice from Mint Capital Advisors Ltd in respect of £500,000 in principal amount of the Convertible Loan Notes issued by the Company on 3 February 2021. Pursuant to the conversion, the Company will issue, in aggregate, 22,222,222 new ordinary shares of £0.01 each in the capital of the Company (the New Ordinary Shares ) at a conversion price of £0.0225 per Ordinary Share. ....
Hemogenyx Pharmaceuticals PLC Announces Conversion of Convertible Loan Notes THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. LONDON, UK / ACCESSWIRE / May 5, 2021 / Hemogenyx Pharmaceuticals plc ( Hemogenyx Pharmaceuticals or the Company )(LSE:HEMO)(OTC PINK:HOPHF) announces that it has received a conversion notice from Mint Capital Advisors Ltd in respect of £500,000 in principal amount of the Convertible Loan Notes issued by the Company on 3 February 2021. ....
As reported in the interim accounts, on 3 September 2020, the company announced that it had signed a binding Heads of Agreement (the Agreement ) with Mayflower Capital Investments Pty Limited ( Mayflower ) to acquire certain contractual gold production and exploration rights held by Mayflower in Republic of Kenya and in Congo Brazzaville. These rights are held by Mayflower through a special purpose vehicle, Mayflower Gold Limited which is incorporated in the United Kingdom.
Under the Agreement, the Company will acquire 100% of the share capital of Mayflower Gold and the options it holds to acquire: (a) 100% of the share capital of Kilimapesa Gold Pty Limited, which holds a 100% interest in the ....
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces its results for the year ended 31 December 2020.
• Demonstrated that HEMO-CAR-T cells are effective against Acute Myloid Leukemia in vitro and in vivo • Developed a novel cell-based platform technology, referred to as CBR, for the treatment of emerging viral diseases, including COVID-19, as well as certain types of cancer ....